Izotropic (FRA:1R3) Total Liabilities: €3.73 Mil (As of Jan. 2026)


FRA:1R3 Izotropic Corp FRA:1R3
28 GF Score
Price €0.14
! 2 Warning Signs
View Full Analysis

What is Izotropic Total Liabilities?

Izotropic FRA:1R3 +5.93% 28 Total Liabilities is €3.73 Mil as of Jan. 2026. GuruFocus rates FRA:1R3 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Izotropic's Total Liabilities for the quarter that ended in Jan. 2026 was €3.73 Mil.

Izotropic's quarterly Total Liabilities increased from Jul. 2025 (€3.42 Mil) to Oct. 2025 (€3.65 Mil) and increased from Oct. 2025 (€3.65 Mil) to Jan. 2026 (€3.73 Mil).

Izotropic's annual Total Liabilities increased from Apr. 2023 (€2.38 Mil) to Apr. 2024 (€2.78 Mil) and increased from Apr. 2024 (€2.78 Mil) to Apr. 2025 (€3.36 Mil).


Izotropic Total Liabilities Historical Data

* Premium members only.

The historical data trend for Izotropic's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Izotropic Total Liabilities Chart

Izotropic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 0.11 1.94 2.38 2.78 3.36

Izotropic Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.47 3.36 3.42 3.65 3.73
FRA:1R3
28GF Score
Izotropic Corp FRA:1R3
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Izotropic Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Izotropic's Total Liabilities for the fiscal year that ended in Apr. 2025 is calculated as

Total Liabilities=Total Assets (A: Apr. 2025 )-Total Equity (A: Apr. 2025 )
=0.264--3.093
=3.36

Izotropic's Total Liabilities for the quarter that ended in Jan. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.684+(0.042+-1.873501354055E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.73

Total Liabilities=Total Assets (Q: Jan. 2026 )-Total Equity (Q: Jan. 2026 )
=0.423--3.302
=3.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €3.73 Mil mean?
Izotropic (FRA:1R3) has a Total Liabilities of €3.73 Mil as of Jan. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Izotropic and its competitors.
Is Izotropic's Total Liabilities too high?
Izotropic's current Total Liabilities is €3.73 Mil. Overall, Izotropic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Izotropic's Total Liabilities compare to TMO and DHR?
Izotropic's Total Liabilities of €3.73 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Izotropic and its competitors. Izotropic's current Total Liabilities is €3.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Izotropic stock overvalued right now?
Izotropic (FRA:1R3) has a current Total Liabilities of €3.73 Mil. The current Total Liabilities is €3.73 Mil. Izotropic's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Izotropic (FRA:1R3), the current Total Liabilities is €3.73 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Izotropic Business Description

Address 800 - 15355 24th Avenue, Suite 424, Surrey, BC, CAN, V4A 2H9
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
28GF Score

Get the complete analysis for FRA:1R3

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price